TGA clears new diagnostic test for meningitis and encephalitis infections

The Therapeutic Goods Administration (TGA) has approved Qiagen’s QIAstat-Dx Meningitis/Encephalitis (ME) Panel, expanding access to rapid molecular testing for pathogens linked to central nervous system (CNS) infections.

The approval introduces a multiplex PCR-based diagnostic solution designed to support faster clinical decision-making in acute care environments, enabling clinicians to identify the underlying causes of meningitis and encephalitis more efficiently.

Meningitis and encephalitis remain serious threats in Australia. Invasive meningococcal disease still causes roughly 100 cases a year in Australia, with a death rate of around 5-10%, and the illness can progress to severe outcomes within hours of the onset of first symptoms. Encephalitis adds further complexity where even with molecular testing fewer than half of CNS infection cases result in a confirmed cause. Historically, patients presenting with suspected CNS infections often received broad-spectrum antibiotics or antivirals while remaining hospitalised for around a week awaiting results from reference laboratory testing.

The QIAstat-Dx ME Panel can detect 16 common bacterial, viral and fungal pathogens from a single cerebrospinal fluid (CSF) sample within approximately one hour. The panel includes targets such as cytomegalovirus (CMV) and Streptococcus pyogenes, providing clinicians with actionable diagnostic insights during critical stages of patient management.

“Ensuring that the right test reaches the right patient at the right time is fundamental to strengthening public health preparedness and improving patient outcomes,” said Piers Murray, Head of Sales at Qiagen Australia and New Zealand. “Broader access to syndromic testing supports earlier and accurate identification of serious infections, enabling confident clinical decisions.”

A new review examining seven studies assessed the diagnostic performance of QIAstat-Dx ME (QIA-ME) across 1000+ clinical CSF samples. The review reported positive percent agreement (PPA) ranging from 90.6% to 100%, while negative percent agreement (NPA) reported in three of the studies ranged from 75% to 97.7%.

Three studies directly compared QIA-ME with the currently available BioFire FilmArray Meningitis/Encephalitis Panel (FA-ME), finding minimal differences in performance between the two platforms. The findings supported the analytical robustness of QIA-ME, although target-specific limitations were identified, particularly involving herpesviruses such as HSV-1.

The authors of the review also highlighted considerations around panel composition, noting the exclusion of cytomegalovirus and the inclusion of Mycoplasma pneumoniae and Streptococcus pyogenes. Researchers raised questions about the clinical utility of low-prevalence targets, particularly as M. pneumoniae was not detected in any clinical sample analysed.

Despite these considerations, the use of amplification curve analysis and the high level of agreement with FA-ME were identified as factors supporting QIA-ME’s role as a valuable diagnostic tool for CNS infections.

“Prospective real‐world studies are warranted to clarify the clinical value of individual targets and guide appropriate use across varied patient settings,” said the authors.

The latest approval further expands Qiagen’s QIAstat-Dx syndromic testing portfolio in Australia, complementing the existing QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.